SG&A Expense (Quarterly) Chart

View SG&A Expense (Quarterly) for HIMS.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View SG&A Expense (Quarterly) Chart
Start Trial

Historical SG&A Expense (Quarterly) Data

View and export this data back to 2019. Start Trial.
Date Value
March 31, 2026 331.67M
December 31, 2025 314.21M
September 30, 2025 312.83M
June 30, 2025 285.14M
March 31, 2025 279.84M
December 31, 2024 269.11M
September 30, 2024 226.90M
June 30, 2024 185.48M
March 31, 2024 165.12M
December 31, 2023 158.21M
September 30, 2023 151.98M
June 30, 2023 138.36M
March 31, 2023 127.76M
December 31, 2022 113.11M
Date Value
September 30, 2022 104.71M
June 30, 2022 60.49M
March 31, 2022 48.09M
December 31, 2021 42.71M
September 30, 2021 38.29M
June 30, 2021 64.68M
March 31, 2021 88.66M
December 31, 2020 19.31M
September 30, 2020 15.10M
June 30, 2020 26.64M
March 31, 2020 26.84M
December 31, 2019 0.2435M
September 30, 2019 0.4499M
June 30, 2019 0.0166M

SG&A Expense (Quarterly) Range, Past 5 Years

View SG&A Expense (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

SG&A Expense (Quarterly) Benchmarks

View SG&A Expense (Quarterly) Benchmarks
Start Trial
HealthEquity, Inc. 57.96M
Doximity, Inc. 62.03M
GoodRx Holdings, Inc. 107.87M
American Well Corp. 25.45M
Eli Lilly & Co. 2.934B